Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
Hepatocellular lipid content
Insulin sensitivity
Nonalcoholic fatty liver disease
Transmembrane 6 superfamily member 2
Type 2 diabetes
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
25
04
2023
revised:
02
06
2023
accepted:
07
06
2023
medline:
15
8
2023
pubmed:
27
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
Increased hepatocellular lipid content (HCL) is linked to insulin resistance, risk of type 2 diabetes and related complications. Conversely, a single-nucleotide polymorphism (TM6SF2 Males with recent-onset type 2 diabetes with (TM6SF2 The TM6SF2-polymorphism rs58542926 dissociates HCL from insulin resistance in recent-onset type 2 diabetes, which is attenuated by disease duration. This suggests that diabetes-related metabolic alterations dominate over effects of the TM6SF2-polymorphism during early course of diabetes and NAFLD.
Sections du résumé
BACKGROUND AND AIMS
Increased hepatocellular lipid content (HCL) is linked to insulin resistance, risk of type 2 diabetes and related complications. Conversely, a single-nucleotide polymorphism (TM6SF2
METHODS AND RESULTS
Males with recent-onset type 2 diabetes with (TM6SF2
CONCLUSIONS
The TM6SF2-polymorphism rs58542926 dissociates HCL from insulin resistance in recent-onset type 2 diabetes, which is attenuated by disease duration. This suggests that diabetes-related metabolic alterations dominate over effects of the TM6SF2-polymorphism during early course of diabetes and NAFLD.
Identifiants
pubmed: 37495452
pii: S0939-4753(23)00237-5
doi: 10.1016/j.numecd.2023.06.004
pii:
doi:
Substances chimiques
Membrane Proteins
0
TM6SF2 protein, human
0
Triglycerides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1785-1796Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest M.R. is on scientific advisory boards of Boehringer-Ingelheim, Eli Lilly, NovoNordisk and Target RWE, and received investigator-initiated support from Boehringer Ingelheim, Nutricia/Danone and Sanofi–Aventis. All contributions to the manuscript by D.F.M. have been performed when affiliated to the German Diabetes Center, prior to current employment by Boehringer Ingelheim. All other authors have no potential conflicts of interest relevant to this article.